OSU pathology home page

Xue-Feng Bai, MD, PhD

Professor

Xue-Feng Bai, MD, PhD

Phone:

614-292-8649

E-mail:

Email Dr. Bai

Mailing Address:

242A Evans Hall
520 King Ave
Columbus, OH 43201

Biosketch

Xue-Feng Bai, MD, PhD is a Professor in the Experimental Pathology Branch. He earned his MD from the Third Medical University of PLA, Chongqqing China and his PhD at the Karolinska Institute in Stockholm, Sweden. He completed one year of postdoctoral training in the Division of Immunology, Department of Pathology at New York University Medical Center in New York City and two years of postdoctoral training in the Department of Pathology at The Ohio State University Medical Center. Dr. Bai’s research focuses on T cell responses in autoimmune diseases and cancer immunotherapy.

Grants

  • Title: CD200R signaling in tumor growth, immunity and immunotherapy
  • Role: PI
  • Goals: To determine the role of CD200R signaling in regulating tumor microenvironment, and its subsequent role in tumor growth, immunity and immunotherapy.
  • Sponsor: R01 CA211014-01A1 (NIH/NCI)
  • Dates: 08/01/2018 - 07/31/2023

  • Title: IL-27 as a potential immunotherapeutic for cancer
  • Role: PI
  • Goals: To evaluate if AAV-IL-27 can be used as a potential immunotherapeutic in cancer models, and determine the potential mechanisms of action.
  • Sponsor: R01CA229254-01A1 (NIH/NCI)
  • Dates: 07/01/2019 - 06/30/2024

Academic and Medical Appointments

2019 - presentProfessor, Department of Pathology, The Ohio State University

2010 - 2019 Associate Professor, Department of Pathology, The Ohio State University

2005 - present Graduate Faculty (PhD Adviser), The Ohio State University College of Medicine, Integrated Biomedical Science Graduate Program (IBGP)

2003 - present Member, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital & Solove Research Institute. Columbus, OH

Education and Training

1998 - 2000 Postdoctoral Associate, Immunology, The Ohio State University Department of Pathology, Columbus, OH

1998 Ph.D., Karolinska Institute, Stockholm, Sweden

1988 - 1990 Resident, Internal medicine, Third Military Medical University, Chongqing, China.

1988 M.D., Third Military Medical University, Chongqing, China

Selected Publications

Search in PubMed

  • Hu A, Ding M, Zhu J, Liu JQ, Pan X, Ghoshal K and Bai XF (2020) Intra-Tumoral Delivery of IL-27 Using Adeno-Associated Virus Stimulates Anti-tumor Immunity and Enhances the Efficacy of Immunotherapy. Front. Cell Dev. Biol. 8:210. doi: 10.3389/fcell.2020.00210
  • Zhu J, Liu JQ, Shi M, Cheng X, Ding M, Zhang J, Davis JP, Varikuti S, Satoskar AR, Lu L, Pan X, Zheng P, Liu Y, Bai XF. (2018) IL-27 gene therapy induces depletion of regulatory T cells and enhances the efficacy of cancer immunotherapy. JCI Insight Apr 5;3(7).pii: 98745. doi: 10.1172/jci.insight.98745. PMID:29618655.
  • Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Carson WE, Basu S, Bai XF. (2016) A critical role for CD200R signaling in limiting the growth and metastasis of CD200-positive melanoma. J Immunol 197(4):1489-97. doi: 10.4049/jimmunol.1600052. PubMed PMID: 27385779; PubMed Central PMCID: PMC4975953.
  • Liu Z, Liu JQ, Shi Y, Zhu X, Liu Z, Li MS, Yu J, Wu LC, He Y, Zhang G, Bai XF. (2015) Epstein-Barr virus-induced gene 3-deficiency leads to impaired anti-tumor T cell responses and accelerated tumor growth. Oncoimmunology 4(7):e989137. eCollection 2015 Jul.
  • Wang L, Liu JQ, Talebian F, Liu Z, Yu L, Bai XF. (2015) IL-10 enhances CTL-mediated tumor rejection via inhibiting highly suppressive CD4+ T cells and promoting CTL persistence in a murine model of plasmacytoma. Oncoimmunology 4(7):e1014232. eCollection 2015 Jul.
  • Liu Z, Liu JQ, Talebian F, Wu LC, Li S, Bai XF. (2013) IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol 43: 468-479. Article first published online: 15 JAN 2013; DOI: 10.1002/eji.201242930 (Featured “in this issue”).
  • Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y, Bai XF. (2013) Tumor-Derived IL-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis. J Immunol 190: 2415-2423. doi:10.4049/jimmunol.1202535 (Featured “in this issue”)
  • Talebian F, Liu JQ, Liu Z, Khattabi M, He Y, Ganju R, Bai XF. (2012) Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PloS One 7(2):e31442.
  • Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, Yu C, Shi FD, Whitacre CC, Trgovcich J, Bai XF (2012) Increased Th17 and Regulatory T Cell Responses in EBV-Induced Gene 3-Deficient Mice Lead to Marginally Enhanced Development of Autoimmune Encephalomyelitis. J Immunol 188:3099-3106. PMID: 22387555.
  • Zhang X, Liu JQ, Shi Y, Reid HH, Boyd RL, Khattabi M, El-Omrani HY, Zheng P, Liu Y, Bai XF (2012) CD24 on thymic APCs regulates negative selection of myelin antigen-specific T lymphocytes. Eur J Immunol 42:924-935. doi: 10.1002/eji.201142024.
  • Wang L, Liu JQ, Talebian F, El-Omrani FY, Khattabi M, Yu L, Bai XF. (2010) Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy. Eur J Immunol 40(9):2569-79.
  • Liu JQ, Joshi PS, Wang C, El-Omrani HY, Xiao Y, Liu X, Hagan JP, Liu LG, Wu LC, Bai XF. (2010) Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs. J Immunol 184(10):5435-43.
  • Carl JW, Liu JQ, Joshi PS, El-Omrani HY, Yin L, Zheng X, Whitacre CC, Liu Y, Bai XF. (2008) Autoreactive T cells escape clonal deletion in the thymus by a CD24-dependent pathway. J Immunol 181(1):320-8.
  • Liu JQ, Carl JW, Joshi PS, RayChaudhury A, Pu XA, Shi FD, Bai XF. (2007) CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J Immunol 178(10):6227-35.
  • Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E, Shi FD, Ljunggren HG, Bai XF. (2006) Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol 80(6):1345-53.
  • Bai XF, Liu JQ, Joshi PS, Wang L, Yin L, Labanowska J, Heerema N, Zheng P, Liu Y. (2006) Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. Cancer Res 66(16):8241-9.
  • Bai XF, Li O, Zhou Q, Zhang H, Joshi PS, Zheng X, Liu Y, Wang Y, Zheng P, Liu Y. (2004) CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J Exp Med 200(4):447-58.
  • Bai XF, Liu J, Li O, Zheng P, Liu Y. (2003) Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 111(10):1487-96.
  • Bai XF, Liu J, May KF, Guo Y, Zheng P, Liu Y. (2002) B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo. Blood 99(8):2880-9.
  • Bai XF, Bender J, Liu J, Zhang H, Wang Y, Li O, Du P, Zheng P, Liu Y. (2001) Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 2001;167(7):3936-43.